Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
Amer M ZeidanXin HuJessica B LongRong WangXiaomei MaNikolai A PodoltsevScott F HuntingtonSteven D GoreAmy J DavidoffPublished in: Cancer (2017)
Despite limited evidence, HMAs are commonly used to treat older CMML patients. The use of HMAs was associated with a 28% reduction in the risk of death in adjusted analyses. Improvements in supportive care do not appear to account for temporal improvements in OS. Cancer 2017;123:3754-3762. © 2017 American Cancer Society.
Keyphrases
- papillary thyroid
- end stage renal disease
- squamous cell
- healthcare
- chronic kidney disease
- newly diagnosed
- physical activity
- ejection fraction
- palliative care
- bone marrow
- middle aged
- prognostic factors
- peritoneal dialysis
- stem cells
- lymph node metastasis
- quality improvement
- mesenchymal stem cells
- patient reported outcomes
- childhood cancer
- free survival
- health insurance